Merck & Co., Inc. (MRK) the Sole Standout on a Flatlining Dow: General Electric Company (GE), Bank of America Corp (BAC)

Pulling the index up
Merck & Co., Inc. (NYSE:MRK) is up more than 3% so far today. Following news that it can continue its clinical trials of the cholesterol drug Vytorin, Merck & Co., Inc. (NYSE:MRK) has gotten a solid boost. Sales of the drug had been declining over concerns about safety issues, so investors took the news as a sign that, so far, things are looking up for the drug and its producer. Though the best result would have been for the study to conclude due to a lack safety issues, this does bring the drug closer to market, where it can be used to treat heart-related problems like heart attacks, strokes, and other deadly conditions.

The article Merck the Sole Standout on a Flatlining Dow originally appeared on and is written by Jessica Alling.

Fool contributor Jessica Alling has no position in any stocks mentioned, but you can contact her here. The Motley Fool owns shares of Bank of America, Citigroup Inc, and General Electric Company.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.